Angle PLC Announces Interim Results

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company, reported its H1 2025 interim results with revenues of £0.8 million, down from £1.0 million in H1 2024. The company posted a loss of £9.3 million with cash reserves of £5.3 million extending into Q1 2026.

Key operational achievements include successful completion of contracts with Eisai and AstraZeneca, development of DNA Dual Analysis using Illumina NGS technology, and a new collaboration with Myriad Genetics. The company's Parsortix system demonstrated strong results in Eisai's Phase 2 breast cancer trial, particularly with its HER2 assay.

Despite challenging market conditions affecting revenue growth, ANGLE expects 2025 revenues to exceed £1.5 million and anticipates announcing several new high-profile collaborations in the coming months.

Positive

• None.

Negative

• Revenue declined to £0.8 million (H1 2024: £1.0 million)
• Loss increased to £9.3 million (H1 2024: £7.7 million)
• Cash position decreased to £5.3 million (December 2024: £10.4 million)
• 2025 revenue expectations constrained due to customer delays and market challenges
• Limited cash runway extending only into Q1 2026

ANGLE plc

("ANGLE" or "the Company")

Interim Results for the six months ended 30 June 2025

COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONS

Large pharma contracts completed successfully

DNA Dual Analysis Illumina NGS assay for CTC-DNA and ctDNA developed

GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, today announces its unaudited interim results for the six months ended 30 June 2025.

Financial Highlights

• Revenues for the half-year of £0.8 million (H1 2024: £1.0 million)

  • pharma services related revenue £0.3 million (H1 2024: £0.5 million)

  • product-related revenue £0.5 million (H1 2024: £0.5 million)

  • revenues impacted by challenging macro issues including US policy volatility / tariff uncertainty

• Loss for the half-year at £9.3 million, or 2.87 pence per share (H1 2024: loss £7.7 million, or 2.89 pence per share) which includes non-cash foreign exchange movements. Total comprehensive loss for the half year is reduced by 9% to £7.2 million (H1 2024: £7.9 million)

• Operating costs excluding non-cash foreign exchange movements reduced by 12% to £8.0 million (H1 2024: £9.1 million)

• Cash and cash equivalents at 30 June 2025 of £5.3 million (31 December 2024: £10.4 million). R&D Tax Credits due at 30 June 2025 of £1.3 million (31 December 2024: £2.3 million) with receipts of £1.0 million expected shortly. Cash runway extends into Q1 2026 as announced with results in May 2025

Operational Highlights

• Three contracts with large pharma companies, Eisai and AstraZeneca, have been successfully completed demonstrating the value of ANGLE's CTC solutions in this market

• Discussions are ongoing with AstraZeneca, Eisai and other large pharma regarding other new projects building on this success

• Excellent results were achieved by ANGLE's HER2 assay in Eisai's Phase 2 breast cancer trial, demonstrating its ability to reliably track changes in HER2 patient status over time. The HER2 assay and the AR and DDR assays developed for AstraZeneca are all now available on ANGLE's menu of validated tests for other large pharma customers

• Ongoing services agreement with biopharma company, Immatics, is progressing well with ANGLE providing CTC enrichment across three clinical trials including a Phase 3 study in melanoma

• Parsortix system workflow developed using Illumina Next Generation Sequencing (NGS) cancer panels for DNA dual analysis of CTC-DNA and ctDNA from a single blood sample. This unique capability, offered exclusively by ANGLE, opens major new markets by providing a product solution for existing Illumina NGS customers and a key enhancement for pharma companies and healthcare providers undertaking ctDNA analysis

• Ground-breaking research enabled by the Parsortix^® system was published in Nature Medicine leading to spin-out company developing a novel class of drugs to arrest cancer metastasis, in which the Parsortix system is expected to play a pivotal role

• Eleven peer-reviewed scientific papers were published in the six months, bringing the total number of publications to 115 from 45 independent research centres

Outlook

• Customer delays caused by challenging external conditions, including limited access to capital, US policy volatility, and uncertainty over tariffs for both pharma and medtech companies, are continuing to cause significant delays to new projects and collaborations. If these delays continue throughout H2 then 2025 revenues will be constrained significantly and are expected to be in excess of £1.5 million, with revenues shifting into 2026

• The revenue delays have not materially impacted on the cash runway, which with tax credits and tight cost control, provide the Company with working capital into Q1 2026 ahead of which we expect to announce further contracts / collaborations and commercial progress

• Post the period end, a large medtech company collaboration has been secured with Myriad Genetics to transfer an existing tissue-based cancer test to a CTC-based sample using the Parsortix system. The Myriad tissue-based assay is FDA approved as a companion diagnostic and is well-established with a substantial commercial base, which as a CTC-based assay could deliver substantial clinical revenues for ANGLE

• ANGLE has a pipeline of opportunities with multiple large medtech and large pharma companies and expects to announce a number of new high-profile collaborations / contracts in the coming months. Opportunities under discussion include new large pharma contracts, new large medtech collaborations, and partnerships with downstream analysis companies marrying their DNA molecular solutions and protein analysis solutions to a Parsortix CTC sample

• Encouraging discussions progressing with the UK NHS in relation to establishing major clinical studies to formally assess the clinical benefits of analysing CTCs using the Parsortix system with a view to clinical adoption as part of the NHS 10 Year Health Plan

ANGLE Chief Executive, Andrew Newland, commented:

"We have acted decisively to build a strategy for long-term growth whilst maintaining a sharp focus on cost discipline and operational efficiency and successfully delivered on our contracts with large pharma. Our agreement with Myriad Genetics marks a potentially transformational step towards the large-scale commercialisation of the Parsortix system, providing a pathway to CTCs being adopted into routine clinical use. Our priority now is to capitalise fully on ongoing discussions with large pharma, large medtech, and major healthcare providers. Notwithstanding the continued challenging external conditions, we remain confident in ANGLE's ability to deliver long-term value, advancing cancer diagnostics and treatment worldwide."

Details of webcast

A meeting for analysts will be held virtually at 11:00 am BST today. The live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/information-for-investors-angle-plc/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.

For further information:

ANGLE plc Andrew Newland, Chief Executive Ian Griffiths, Finance Director	+44 (0) 1483 343434
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper Sunila de Silva (Corporate Broking) Nigel Birks - Life Science Specialist Sales	+44 (0) 20 7220 0563
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

These Interim Results may contain forward-looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors that could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Group's research and development activities, commercialisation strategies, the uncertainties related to clinical study outcomes and regulatory clearance, obtaining reimbursement and payor coverage, acceptance into national guidelines and the acceptance of the Group's products and services by customers.

Click on, or paste the following link into your web browser, to view the full announcement text:

http://www.rns-pdf.londonstockexchange.com/rns/4985Y_1-2025-9-8.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

What were ANGLE plc's (ANPCY) revenue and losses for H1 2025?

ANGLE reported revenues of £0.8 million (down from £1.0 million in H1 2024) and losses of £9.3 million (compared to £7.7 million in H1 2024).

How much cash does ANGLE plc have and how long will it last?

ANGLE has £5.3 million in cash and cash equivalents as of June 30, 2025, with an additional £1.3 million in R&D Tax Credits due. The cash runway extends into Q1 2026.

What major partnerships did ANGLE announce in 2025?

ANGLE completed contracts with Eisai and AstraZeneca, maintained an ongoing services agreement with Immatics, and secured a new collaboration with Myriad Genetics for CTC-based testing.

What is ANGLE's revenue forecast for full-year 2025?

ANGLE expects 2025 revenues to be in excess of £1.5 million, with some revenue shifting into 2026 due to customer delays and challenging market conditions.

What is ANGLE's new DNA Dual Analysis capability?

ANGLE developed a Parsortix system workflow using Illumina NGS cancer panels that can analyze both CTC-DNA and ctDNA from a single blood sample, offering a unique capability for existing Illumina NGS customers.